Skip to content

Effect of Untact Upper Extremity Rehabilitation Using a Smart Board for Late Subacute and Chronic Patients With Brain Disorder

A Multicenter Confirmation Clinical Trial of Untact Upper Extremity Rehabilitation Using Smart Board for Late Subacute and Chronic Patients With Brain Disorder - a Randomized Single-blinded Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06837363
Enrollment
40
Registered
2025-02-20
Start date
2025-04-01
Completion date
2026-12-31
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Disorder, Home Based Rehabilitation

Brief summary

The aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the Neofect Smart Board by comparing the effects between a group using the home-based Neofect Smart Board and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.

Interventions

DEVICEHome-based Neofect Smart board

a total of 20 sessions of home-based upper limb rehabilitation training using the Neofect Smart board, with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.

a total of 20 sessions of home-based upper limb rehabilitation training using the workbook provided by the research team , with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients with neurological diseases aged 19 to 85 years old * Patients with hemiparesis lasting for more than 3 months due to neurological diseases (stroke, traumatic brain injury, brain tumor) and impaired upper limb function * Patients with shoulder flexor and adductor muscle strength of MRC grade 2 or higher * Patients with shoulder extensor and abductor spasticity of MAS grade 1+ or lower * Participants with sufficient cognitive function to understand the instructions from the researcher and the smart board, and to perform the tasks (K-MMSE ≥21)

Exclusion criteria

* pre-existing significant neurogenic disorders * major psychiatric disorders such as schizophrenia, bipolar disorder, or dementia * History of diseases that caused pain or muscle atrophy in the affected upper limb before the onset of the neurological disease, which interfered with rehabilitation * Severe spasticity of the affected upper limb (Modified Ashworth Scale score ≥3) * skin disorders or open wounds on the affected upper limb * Amputation, fractures, or soft tissue-related diseases or injuries on the affected upper limb * severe pain that interferes with rehabilitation of the affected upper limb (Numeric Rating Scale \> 6) * Inability to maintain a seated posture for more than 10 minutes, which is required for using the smart board * Significant visual impairment to the extent that the screen cannot be recognized when using the smart board

Design outcomes

Primary

MeasureTime frameDescription
Improvement of uper limb score in Fugl-Meyer assessmentWithin 14 days before the intervention, within 2 days after intervention(upper limb motor score in Fugl-Meyer assessment at post-intervention) - (upper limb motor score in Fugl-Meyer assessment at baseline) Higher scores mean a better outcome

Countries

South Korea

Contacts

CONTACTWon Hyuk Chang
wh.chang@samsung.com+82-2-3410-6889

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026